Targeting obesity-related dysfunction in hormonally driven cancers

Area of Science:

• Oncology
• Metabolic Syndrome Research
• Cancer Pathogenesis

Background:

• Obesity is a major risk factor for over 13 cancer types, many hormonally driven, leading to increased incidence and morbidity.
• Rising adult obesity rates predict a growing cancer burden.
• Obesity-related dysfunction impacts cancer pathogenesis and treatment resistance via hormonal and inflammatory pathways.

Purpose of the Study:

• To explore the mechanisms linking obesity to cancer development and treatment resistance.
• To highlight the necessity of investigating non-pharmacological interventions for obesity-mediated cancer.
• To emphasize the role of diet, exercise, and bariatric surgery in reversing obesity's cancer-promoting effects.

Main Methods:

• Review of mechanisms including insulin, leptin, adipokine, and aromatase signaling.
• Analysis of adiposity's influence on tumor vascularity and inflammation.
• Discussion of emerging trials for non-pharmacological approaches.

Main Results:

• Obesity influences cancer through hormonal signaling (insulin, leptin, adipokines, aromatase) and the tumor microenvironment (vascularity, inflammation).
• Non-pharmacological interventions show promise in targeting obesity-driven cancer mechanisms.
• Rigorous trials with defined endpoints are needed to evaluate lifestyle interventions.

Conclusions:

• Understanding obesity's impact on cell signaling and systemic factors is critical for oncogenesis.
• Promoting lifestyle intervention trials is essential for cancer prevention and treatment.
• Diet, exercise, and bariatric surgery are key strategies to mitigate obesity-related cancer risks.